Carolyn Myers has joined the board of Mayne Pharma.
Myers is an experienced pharmaceutical executive having held senior leadership roles at Allergan, Forest Labs, Mylan (now Viatris) and Pharmacia (now Pfizer). She has 30 years of experience in the pharmaceutical industry and is currently CEO of FendX technologies, a medical technology company formed to develop and commercialize products using a unique pathogenrepelling technology.
She also is principal of BioEnsemble, providing consulting services to small and mid-size pharma, biotech and medical technology companies. Previously, she was vice president of Global Alliance Management and International Business Development at Allergan, vice president of marketing at Forest Laboratories, president of Dey Laboratories and president of Mylan Technologies.
[Read more: Mayne Pharma names Frank Condella to board chair]
“We are delighted to welcome Carolyn to the board of Mayne Pharma. Carolyn has a distinguished track record of success in creating, growing, and leading health care businesses. She has deep experience in business development, sales and marketing, strategy, portfolio management and R&D and has led the launch of over 20 brand products,” Mayne's chair Frank Condella said.
“I am pleased to be joining the board at this important time in Mayne Pharma’s development. As nominee of the company’s largest shareholder, our interests are aligned. I am committed to supporting the successful commercialization of Nextstellis oral contraceptive in the world’s largest pharmaceutical market,” Myers said.
[Read more: FDA clears Nextstellis from Mayne, Mithra]
Myers is a steering committee member of Mid Atlantic Bio Angels, a committee member of Golden Seeds and an independent board member of Hyloris Pharmaceuticals. She has a Ph.D. from the University of British Columbia and a Masters in Business Administration from Rutgers University.